KLUS Pharma is the US subsidiary of Kelun-Biotech, a China-based corporation with a broad pipeline targeting unmet needs in oncology and other serious diseases.
Our Company
KLUS Pharma is based in Cranbury, NJ, and is the wholly-owned U.S. subsidiary of Kelun-Biotech, a corporation based in Chengdu, China.
We strive to discover and develop innovative biologics for the treatment of cancer and other serious diseases, addressing unmet needs and creating affordable medicines.
We have a rich pipeline of small and large molecules targeting solid tumors and other indications with multiple ongoing clinical trials.
Our Approach
Our antibodies undergo affinity maturation, humanization, and Fc engineering, generating lead candidates with optimal efficacy and safety.
Our platform supports a wide variety of bispecific designs which allows for flexibility in selecting the optimal design based on intended MOA.
Our third-generation ADC platform allows for site-specific conjugation of potent warheads to antibodies, with a variety of linkers and tunable DAR.
Jul 26, 2022
Kelun-Biotech Announces Oncology Research Collaboration and License Agreement with MSD
Jun 28, 2022
Kelun-Biotech's small molecule A400/EP0031 obtained IND approval from the FDA submitted by collaboration partner Ellipses Pharma
May 29, 2022
Clinical updates will be presented at 2022 ASCO for the Phase 1 dose-expansion study of A166 in HER2+ metastatic breast cancer.